Stoke Therapeutics (STOK) Cash & Equivalents (2022 - 2025)
Historic Cash & Equivalents for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $83.4 million.
- Stoke Therapeutics' Cash & Equivalents fell 4440.99% to $83.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.4 million, marking a year-over-year decrease of 4440.99%. This contributed to the annual value of $128.0 million for FY2024, which is 3314.79% down from last year.
- As of Q3 2025, Stoke Therapeutics' Cash & Equivalents stood at $83.4 million, which was down 4440.99% from $101.5 million recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Cash & Equivalents ranged from a high of $274.8 million in Q1 2025 and a low of $67.8 million during Q2 2022
- Over the past 4 years, Stoke Therapeutics' median Cash & Equivalents value was $150.0 million (recorded in 2024), while the average stood at $150.2 million.
- As far as peak fluctuations go, Stoke Therapeutics' Cash & Equivalents surged by 18346.67% in 2023, and later crashed by 4755.32% in 2025.
- Over the past 4 years, Stoke Therapeutics' Cash & Equivalents (Quarter) stood at $113.6 million in 2022, then surged by 68.59% to $191.4 million in 2023, then crashed by 33.15% to $128.0 million in 2024, then crashed by 34.84% to $83.4 million in 2025.
- Its Cash & Equivalents was $83.4 million in Q3 2025, compared to $101.5 million in Q2 2025 and $274.8 million in Q1 2025.